February, marked globally as Cancer Prevention Month, is a time to renew our commitment to reducing the impact of cancer. This month serves as a reminder of the significant strides made in cancer research, treatment, and prevention. However, it also underscores the need for continued vigilance and...

New technology is impacting preventive care and advancing home health care in countless ways, offering more convenience, efficiency, and cost savings. Technology is revolutionizing preventative care, transforming how health care providers diagnose, treat, and monitor patient health. Home health...

Cancer can present itself in many ways and has varying and debilitating symptoms. However, some forms of cancer are chronic and could pose more challenges regarding health care management. Cancer is a serious condition with various causes, and different types of cancer affect people differently....

Inflation directly affects the prices of prescription drugs in the U.S., but the Inflation Reduction Act can help combat the soaring prices and make them accessible to patients. According to a 2022 survey , one in three adults says they haven’t taken prescription medications due to the...

Key takeaways: High blood pressure and cancer claim millions of lives every year Chances of developing potentially fatal disease can be significantly reduced through a healthy diet Fruits and vegetables offer multiple benefits Fatty fish is the best meat for preventative care Some of the...

An apple a day isn’t quite enough to keep the doctor away. Read our guide to what real preventative care requires. Key Takeaways: Prioritizing preventative steps delivers multiple benefits. Increased personal awareness, better budgeting, and easier condition management become...

Lynparza (olaparib tablets) is the first poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the treatment of patients with breast cancer whose tumors have a specific inherited genetic mutation. Lynparza is already approved in the United States as a treatment for a number of other cancers,...

Patients with HER2 breast cancer will have a new treatment option available later this year, following the US Food and Drug Administration's (FDA) approval of the first extended adjuvant treatment for the condition. Nerlynx (neratinib), a kinase inhibitor from Puma Biotechnology, was granted FDA...

A Phase III OlympiAD trial of Lynparza (olaparib) tablets for treating patients with HER2-negative gBRCA-mutated metastatic breast cancer has yielded positive results with a "statistically-significant and clinically-meaningful improvement in progression-free survival". Pharmaceutical firm...